Determining Which Patients Will Benefit from GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM

In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

After more than a decade of limited progress, the clinical management of advanced biliary tract cancers is rapidly changing. The introduction of new systemic therapies and the increased understanding of clinically actionable mutations in biliary tract cancers have led to the development of several biomarker-guided treatments and other promising strategies. In this activity, an oncology advanced practice provider discusses the latest clinical data regarding recently validated and forthcoming therapeutic strategies for patients with biliary tract cancers and the nurse’s role in improving patient outcomes through patient education, monitoring for and managing treatment-related toxicities, and counseling patients on therapeutic options, including clinical trial enrollment.

In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma.

In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered.

In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis.

Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care.

In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.

In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies.

In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza.

In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM.